Sun Pharma Swears By Time-tested U.S., India Markets As It Builds Specialty Business
This article was originally published in PharmAsia News
Executive Summary
India’s Sun Pharma has beaten street expectations in recent years, and as the business now inches beyond the $2 billion sales mark, largely from the United States, Sun’s challenges are becoming more complex. Founder Dilip Shanghvi sat down with PharmAsia News for an exclusive interview to discuss the company’s future.